A 20 year old unremarkable oncolytic viral immunotherapy company, IPO’d at the start of 2023 lacking any notable investors, questionable science, and insufficient runway
Share this post
Genelux: Even the insiders are fleeing
Share this post
A 20 year old unremarkable oncolytic viral immunotherapy company, IPO’d at the start of 2023 lacking any notable investors, questionable science, and insufficient runway